RU2725006C2 - Терапия стволовыми клетками при патологиях эндометрия - Google Patents
Терапия стволовыми клетками при патологиях эндометрия Download PDFInfo
- Publication number
- RU2725006C2 RU2725006C2 RU2017101147A RU2017101147A RU2725006C2 RU 2725006 C2 RU2725006 C2 RU 2725006C2 RU 2017101147 A RU2017101147 A RU 2017101147A RU 2017101147 A RU2017101147 A RU 2017101147A RU 2725006 C2 RU2725006 C2 RU 2725006C2
- Authority
- RU
- Russia
- Prior art keywords
- subject
- endometrial
- bmdsc
- autologous
- cells
- Prior art date
Links
- 230000002357 endometrial effect Effects 0.000 title claims abstract description 60
- 230000007170 pathology Effects 0.000 title abstract description 10
- 238000009168 stem cell therapy Methods 0.000 title description 7
- 238000009580 stem-cell therapy Methods 0.000 title description 7
- 238000000034 method Methods 0.000 claims abstract description 51
- 208000002777 Gynatresia Diseases 0.000 claims abstract description 41
- 210000000130 stem cell Anatomy 0.000 claims abstract description 35
- 230000008929 regeneration Effects 0.000 claims abstract description 25
- 238000011069 regeneration method Methods 0.000 claims abstract description 25
- 206010051909 Endometrial atrophy Diseases 0.000 claims abstract description 23
- 210000000685 uterine artery Anatomy 0.000 claims abstract description 21
- 102100040120 Prominin-1 Human genes 0.000 claims description 77
- 238000011282 treatment Methods 0.000 claims description 28
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 22
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 22
- 210000001185 bone marrow Anatomy 0.000 claims description 20
- 238000002617 apheresis Methods 0.000 claims description 14
- 210000004291 uterus Anatomy 0.000 claims description 14
- 208000028685 Asherman syndrome Diseases 0.000 claims description 13
- 210000002565 arteriole Anatomy 0.000 claims description 13
- 238000002513 implantation Methods 0.000 claims description 11
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 8
- 230000003054 hormonal effect Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 210000001161 mammalian embryo Anatomy 0.000 claims description 6
- 230000032692 embryo implantation Effects 0.000 claims description 5
- 230000001483 mobilizing effect Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 5
- 230000006698 induction Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 43
- 238000002659 cell therapy Methods 0.000 description 18
- 210000004204 blood vessel Anatomy 0.000 description 10
- 230000027758 ovulation cycle Effects 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 9
- 230000005906 menstruation Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002657 hormone replacement therapy Methods 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 208000000995 spontaneous abortion Diseases 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000002346 layers by function Substances 0.000 description 7
- 230000035935 pregnancy Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 206010000234 Abortion spontaneous Diseases 0.000 description 6
- 208000037093 Menstruation Disturbances Diseases 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000002175 menstrual effect Effects 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 201000001389 adhesions of uterus Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000754 myometrium Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- 201000010260 leiomyoma Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 description 3
- 101710196131 Aldehyde dehydrogenase 1 Proteins 0.000 description 3
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010041660 Splenomegaly Diseases 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 231100000544 menstrual irregularity Toxicity 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108010005465 AC133 Antigen Proteins 0.000 description 2
- 102000005908 AC133 Antigen Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 101150017554 LGR5 gene Proteins 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000035175 Oligomenorrhea Diseases 0.000 description 2
- 206010030295 Oligomenorrhoea Diseases 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000010102 embolization Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000603 stem cell niche Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000035002 Pregnancy of unknown location Diseases 0.000 description 1
- 206010036603 Premature rupture of membranes Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010046764 Uterine atrophy Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- -1 and after five days Proteins 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000030373 chronic endometritis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037211 monthly cycles Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000002660 stem cell treatment Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100001042 uterine atrophy Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013121P | 2014-06-17 | 2014-06-17 | |
| US62/013,121 | 2014-06-17 | ||
| PCT/IB2015/001715 WO2015193737A1 (en) | 2014-06-17 | 2015-06-05 | Stem cell therapy in endometrial pathologies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017101147A RU2017101147A (ru) | 2018-07-17 |
| RU2017101147A3 RU2017101147A3 (cg-RX-API-DMAC7.html) | 2019-02-06 |
| RU2725006C2 true RU2725006C2 (ru) | 2020-06-29 |
Family
ID=54329860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017101147A RU2725006C2 (ru) | 2014-06-17 | 2015-06-05 | Терапия стволовыми клетками при патологиях эндометрия |
Country Status (22)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2741621C1 (ru) * | 2020-09-25 | 2021-01-28 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ лечения внутриматочных синехий |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
| BR112015023510A2 (pt) | 2013-03-15 | 2017-10-10 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para o diagnóstico, prognóstico e tratamento de câncer metastático |
| SMT202400270T1 (it) | 2014-06-17 | 2024-07-09 | Asherman Therapy S L | Terapia con cellule staminali in patologie endometriali |
| RU2771328C2 (ru) * | 2016-06-23 | 2022-04-29 | Титон Биотек, Инк. | Клетки, экспрессирующие рецептор паратиреоидного гормона 1, и их применение |
| RU2699029C1 (ru) * | 2018-12-10 | 2019-09-03 | Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") | Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке |
| CN117979980A (zh) | 2021-07-23 | 2024-05-03 | 车医科学大学校产学协力团 | 用于预防或治疗阿谢曼综合征的包含分离的线粒体作为活性成分的药物组合物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100249015A1 (en) * | 2007-02-26 | 2010-09-30 | John Francis Martin | Use of VEGF in the Treatment of Retarded Fetal Growth in Pregnancy |
| RU2515475C1 (ru) * | 2012-11-15 | 2014-05-10 | Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК | Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2054197A1 (en) | 1989-05-05 | 1990-11-06 | Christopher O'neill | Fertility enhancement |
| US6979533B2 (en) | 1992-06-12 | 2005-12-27 | The Trustees Of The University Of Pennsylvania | Determination of endometrial receptivity toward embryo implantation |
| CA2203718A1 (en) | 1997-04-25 | 1998-10-25 | University Of British Columbia | Cadherin-11 as an indicator of viable pregnancy |
| IL127896A0 (en) | 1998-12-31 | 1999-10-28 | Gail Laster | A novel treatment for preeclampsia and related diseases |
| AU2001240096A1 (en) | 2000-03-08 | 2001-09-17 | Rebecca L. Dubowy | Methods of diagnosing and monitoring endometrial glandular development |
| AU2001264900A1 (en) | 2000-05-24 | 2001-12-03 | Schering Aktiengesellschaft | Pharmaceutical use of fibulin-1 |
| US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| AUPR673001A0 (en) | 2001-07-31 | 2001-08-23 | Prince Henry's Institute Of Medical Research | Pregnancy-related enzyme activity |
| DE10139874A1 (de) | 2001-08-10 | 2003-04-30 | Schering Ag | Humane Mater-Proteine |
| GB0201284D0 (en) | 2002-01-21 | 2002-03-06 | Isis Innovation | Screening methods for contraceptive and fertility agents |
| US20030186300A1 (en) | 2002-03-20 | 2003-10-02 | Ali Akoum | Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions |
| CA2489568A1 (en) | 2002-05-14 | 2004-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Endometrial genes in endometrial disorders |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| EP1525215B1 (de) | 2002-08-02 | 2006-09-06 | Schering Aktiengesellschaft | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie |
| DE10361928A1 (de) | 2002-12-21 | 2004-07-01 | Universität Leipzig | Verfahren und Mittel zur Bestimmung von bestimmten Zuständen bzw. Veränderungen im Uterusepithel und im Epithel anderer Organe |
| WO2005018796A1 (en) | 2003-08-21 | 2005-03-03 | Pamgene B.V. | Microarray support for bioprobe synthesis |
| CN1863905A (zh) | 2003-09-08 | 2006-11-15 | 得克萨斯系统大学董事会 | 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物 |
| EP1670902A4 (en) | 2003-09-08 | 2008-05-07 | Univ Texas | METHOD AND COMPOSITION FOR ENHANCING i IN VITRO /i EMBRYO DEVELOPMENT BY SUPPLEMENTING CULTURE MEDIUM WITH PROSTAGLANDIN OR A PROSTAGLANDIN ANALOG |
| WO2005061725A1 (en) | 2003-12-23 | 2005-07-07 | Mount Sinai Hospital | Methods for detecting markers associated with endometrial disease or phase |
| JP2008501035A (ja) | 2004-05-28 | 2008-01-17 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 妊孕性関連障害の治療におけるｉｌ−１７の使用 |
| RU2434645C2 (ru) * | 2006-03-31 | 2011-11-27 | Конинклейке Филипс Электроникс, Н.В. | Системы и методы измерения клеток, использующие ультракороткую т2*-релаксометрию |
| JP2007278750A (ja) | 2006-04-04 | 2007-10-25 | Ono Pharmaceut Co Ltd | プロスタグランジン類及びその類縁体の定量方法 |
| WO2008036374A2 (en) * | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| US9259233B2 (en) * | 2007-04-06 | 2016-02-16 | Hologic, Inc. | Method and device for distending a gynecological cavity |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| WO2013166281A1 (en) * | 2012-05-02 | 2013-11-07 | Cedars-Sinai Medical Center | Bi-functional compositions for targeting cells to diseased tissues and methods of using same |
| EP2348318A1 (en) | 2010-01-21 | 2011-07-27 | Equipo Ivi Investigación, S.L. | Diagnostic method for endometrial receptivity |
| WO2013057316A2 (en) | 2011-10-21 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for assessing endometrial receptivity of a patient after controlled ovarian hyperstimulation |
| JP6329078B2 (ja) | 2011-11-30 | 2018-05-23 | エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ | 生物学的モニタリングのためのアネキシンｖのマイクロ粒子ポリペプチドに対するｇｍ１ガングリオシドの比 |
| WO2014001244A1 (en) | 2012-06-27 | 2014-01-03 | Roche Diagnostics Gmbh | MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD |
| JP6684263B2 (ja) | 2014-03-21 | 2020-04-22 | アイジェノミクス エセ．エレ． | 子癇前症の早期検出 |
| SMT202400270T1 (it) | 2014-06-17 | 2024-07-09 | Asherman Therapy S L | Terapia con cellule staminali in patologie endometriali |
-
2015
- 2015-06-05 SM SM20240270T patent/SMT202400270T1/it unknown
- 2015-06-05 CN CN201580043147.1A patent/CN107073040A/zh active Pending
- 2015-06-05 SI SI201530822T patent/SI3158057T1/sl unknown
- 2015-06-05 WO PCT/IB2015/001715 patent/WO2015193737A1/en not_active Ceased
- 2015-06-05 CN CN202310575540.1A patent/CN116747241A/zh active Pending
- 2015-06-05 HU HUE15781411 patent/HUE044823T2/hu unknown
- 2015-06-05 SM SM20190400T patent/SMT201900400T1/it unknown
- 2015-06-05 PL PL22150013.5T patent/PL4012023T3/pl unknown
- 2015-06-05 JP JP2016573587A patent/JP6920062B2/ja active Active
- 2015-06-05 EP EP15781411.2A patent/EP3158057B1/en active Active
- 2015-06-05 BR BR112016029558A patent/BR112016029558A2/pt not_active Application Discontinuation
- 2015-06-05 US US15/318,825 patent/US11129851B2/en active Active
- 2015-06-05 RU RU2017101147A patent/RU2725006C2/ru active
- 2015-06-05 PL PL15781411T patent/PL3158057T3/pl unknown
- 2015-06-05 EP EP22150013.5A patent/EP4012023B1/en active Active
- 2015-06-05 RS RS20240690A patent/RS65719B1/sr unknown
- 2015-06-05 HR HRP20240798TT patent/HRP20240798T1/hr unknown
- 2015-06-05 PT PT15781411T patent/PT3158057T/pt unknown
- 2015-06-05 LT LTEP15781411.2T patent/LT3158057T/lt unknown
- 2015-06-05 DK DK19169309.2T patent/DK3569697T3/da active
- 2015-06-05 ES ES15781411T patent/ES2736117T3/es active Active
- 2015-06-05 HU HUE19169309A patent/HUE058328T2/hu unknown
- 2015-06-05 RS RSP20190913 patent/RS59210B1/sr unknown
- 2015-06-05 HR HRP20220419TT patent/HRP20220419T1/hr unknown
- 2015-06-05 LT LTEP19169309.2T patent/LT3569697T/lt unknown
- 2015-06-05 RS RS20220339A patent/RS63093B1/sr unknown
- 2015-06-05 PL PL19169309T patent/PL3569697T3/pl unknown
- 2015-06-05 CA CA2952559A patent/CA2952559C/en active Active
- 2015-06-05 AU AU2015275798A patent/AU2015275798B2/en active Active
- 2015-06-05 HR HRP20191240 patent/HRP20191240T1/hr unknown
- 2015-06-05 SM SM20220155T patent/SMT202200155T1/it unknown
- 2015-06-05 PT PT191693092T patent/PT3569697T/pt unknown
- 2015-06-05 HU HUE22150013A patent/HUE067463T2/hu unknown
- 2015-06-05 MX MX2016016756A patent/MX377300B/es active IP Right Grant
- 2015-06-05 ES ES19169309T patent/ES2910306T3/es active Active
- 2015-06-05 ES ES22150013T patent/ES2983444T3/es active Active
- 2015-06-05 DK DK15781411.2T patent/DK3158057T3/da active
- 2015-06-05 TR TR2019/10410T patent/TR201910410T4/tr unknown
- 2015-06-05 EP EP19169309.2A patent/EP3569697B8/en active Active
- 2015-06-05 SI SI201531822T patent/SI3569697T1/sl unknown
-
2019
- 2019-07-16 CY CY20191100753T patent/CY1122615T1/el unknown
-
2020
- 2020-06-12 JP JP2020102340A patent/JP2020138984A/ja active Pending
-
2022
- 2022-04-05 CY CY20221100258T patent/CY1125938T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100249015A1 (en) * | 2007-02-26 | 2010-09-30 | John Francis Martin | Use of VEGF in the Treatment of Retarded Fetal Growth in Pregnancy |
| RU2515475C1 (ru) * | 2012-11-15 | 2014-05-10 | Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК | Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте |
Non-Patent Citations (8)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2741621C1 (ru) * | 2020-09-25 | 2021-01-28 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ лечения внутриматочных синехий |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2725006C2 (ru) | Терапия стволовыми клетками при патологиях эндометрия | |
| Zhao et al. | Exosomes derived from adipose mesenchymal stem cells restore functional endometrium in a rat model of intrauterine adhesions | |
| Tan et al. | Autologous menstrual blood-derived stromal cells transplantation for severe Asherman's syndrome | |
| Zhang et al. | Using 17β‐estradiol heparin‐poloxamer thermosensitive hydrogel to enhance the endometrial regeneration and functional recovery of intrauterine adhesions in a rat model | |
| Gao et al. | Uterine artery embolization followed by dilation and curettage within 24 hours compared with systemic methotrexate for cesarean scar pregnancy | |
| Puente Gonzalo et al. | Intrauterine infusion of platelet-rich plasma for severe Asherman syndrome: a cutting-edge approach | |
| US12350292B2 (en) | Bioactive renal cells for the treatment of chronic kidney disease | |
| de Miguel‐Gómez et al. | Strategies for managing Asherman's syndrome and endometrial atrophy: since the classical experimental models to the new bioengineering approach | |
| Zafardoust et al. | Intraovarian administration of autologous menstrual blood derived-mesenchymal stromal cells in women with premature ovarian failure | |
| Santamaria et al. | Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome? | |
| HK40075844A (en) | Stem cell therapy in endometrial pathologies | |
| HK40075844B (en) | Stem cell therapy in endometrial pathologies | |
| HK1242600A1 (en) | Stem cell therapy in endometrial pathologies | |
| Ventura et al. | Advanced Cell Therapy for Asherman's Syndrome | |
| Igboeli et al. | CASE REPORT Open Access | |
| CN110393790B (zh) | 促黄体生成素在抑制髓系白血病发展的用途 | |
| Santamaria et al. | Hysteroscopy and Stem Cell Therapy to Approach Refractory Asherman’s Syndrome | |
| Amer et al. | Organic Tissue Grafts Following Intrauterine Adhesiolysis | |
| Mei et al. | Human umbilical cord mesenchymal stem cells (hUCMSCs) promotes the regeneration of severe endometrial damage in a rat model | |
| Seifer et al. | Stem cell therapies for atrophic endometrium and Asherman's syndrome | |
| Al-Sakkal et al. | Osseous Metaplasia of the endometrium A case report and review of the literature |